News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
KEYMED BIO-B (02162.HK) Receives USD257 million Upfront Payment from Sale of Ouro Medicines
KEYMED BIO-B (02162.HK) announced that the merger and acquisition agreement involving the Group’s NewCo partner Ouro Medicines has been completed, and the Group has received an upf...
Reset
Send
The window will close in 5 seconds
KEYMED BIO-B (02162.HK) Receives USD257 million Upfront Payment from Sale of Ouro Medicines
Close
Recommend
2
Positive
1
Negative
0
 
SHORT SELL
 
STOCK INFO
aacat by AASTOCKS
Open a new trading account to get 1 Intel/Selected Gold ETF share!

KEYMED BIO-B (02162.HK)  -0.650 (-1.101%)    Short selling $14.79M; Ratio 6.987%   announced that the merger and acquisition agreement involving the Group’s NewCo partner Ouro Medicines has been completed, and the Group has received an upfront payment of USD257 million.

Under the terms of the agreement, Gilead acquired 100% equity interest in Ouro Medicines for an upfront payment of USD1.675 billion and up to USD500 million in potential milestone payments. As a shareholder of Ouro Medicines, the Group received approximately USD257 million in upfront payment and is entitled to receive up to approximately USD70 million in milestone payments. In addition, the exclusive licensing agreement entered into between the Group and Ouro Medicines in November 2024 remains effective, under which up to USD610 million in milestone payments and tiered royalties on net sales will be fulfilled by Gilead and Lakefront.

Related News CMSI: Three Reasons for Recent Underperformance of Pharma Sector vs HSI; Top Picks INNOVENT BIO (01801.HK), HANSOH PHARMA (03692.HK) and KEYMED BIO-B (02162.HK)
Through this transaction, Lakefront acquired the vast majority of the team and operating assets of Ouro Medicines and will collaborate with Gilead on the subsequent development of CM336/OM336. Lakefront will be responsible for the ongoing and future Phase I/II clinical trials of CM336/OM336, while Gilead will lead registration and late-stage studies. Gilead will retain exclusive global commercialization rights (excluding Greater China). (sl/da)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-06-05 16:25.)

Auto-translated by AI
View Original Text
This article was automatically translated by AI, the original language version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation.

AASTOCKS Financial News
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.